At a Glance
- Companies: AstraZeneca and Immunai
- Deal value: Up to $37.5 million
- Focus area: Oncology and clinical data analysis
- Platform: AMICA-OS immune profiling system
- Next steps: Expand use across clinical programmes
What happened?
AstraZeneca has expanded its collaboration with Immunai, with the deal worth up to $37.5 million. The partnership will extend the use of Immunai’s AMICA-OS platform further into AstraZeneca’s oncology clinical development pipeline.
Why does it matter?
Understanding how the immune system responds to cancer therapies remains a major challenge in oncology. By applying AI-driven immune profiling to clinical data, the collaboration aims to generate deeper insights into patient response and improve trial design and outcomes.
Who’s behind it?
AstraZeneca is a global biopharmaceutical company with a strong oncology portfolio. Immunai is an AI-driven biotech focused on mapping the immune system using multimodal data and machine learning.
How was it achieved?
Immunai’s AMICA-OS platform integrates large-scale immune data with AI models to analyse how different cell types behave during treatment. AstraZeneca will use these tools to interrogate clinical datasets and identify biomarkers or response patterns.
What’s next?
The expanded collaboration will see Immunai’s platform applied across additional clinical programmes. The goal is to refine patient stratification, optimise therapies and potentially guide future drug development decisions.